14.9: Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.

Mapping genetic differences associated with disease has facilitated the discovery of drug targets. For example, the identification of HMG-CoA reductase as the rate-limiting enzyme in LDL cholesterol synthesis emerged from studies of Familial Hypercholesterolemia (FH), leading to the development of statins. More recently, PCSK9 was recognized as a therapeutic target after studies showed that individuals with loss-of-function mutations in this gene had significantly lower LDL cholesterol levels and reduced cardiovascular risk. Because of that, PCSK9 inhibitors such as alirocumab and evolocumab have been developed and approved for FH treatment.

Genetic studies have also identified protective variants in genes like APOC3, which encodes apolipoprotein C-III. Loss-of-function mutations in APOC3 result in lower plasma triglyceride levels and reduced risk of coronary artery disease. Similarly, variants in SLC30A8, a gene encoding a zinc transporter in pancreatic β-cells, have been linked to decreased susceptibility to type 2 diabetes, suggesting new pathways for therapeutic intervention.

SNP arrays and gene expression profiling are widely employed to detect genetic loci associated with disease. “Gene hunting” strategies enable researchers to identify genes or mutations associated with specific disease phenotypes. Expression arrays also facilitate the identification of gene regulation changes in diseased versus healthy tissue, offering insights into disease mechanisms and drug responsiveness. Such approaches have guided the development of therapies for cystic fibrosis, where CFTR mutations have been targeted by agents like ivacaftor and lumacaftor.

Pharmacogenomics not only identifies therapeutic targets but also enhances clinical trial design by selecting genetically predisposed subpopulations more likely to respond to specific interventions. This precision reduces trial failures and expedites regulatory approval. Moreover, by linking genotypes to drug efficacy, pharmacogenomics paves the way for personalized medicine, optimizing treatment strategies based on an individual’s genomic profile rather than generalized models.